A New Chapter in the Management of Hypertrophic Cardiomyopathy Cardiac Myosin Inhibitors /
In the recent years, there has been a significant breakthrough in the treatment of hypertrophic cardiomyopathy. New precision molecules have been developed and successfully applied in clinical trials. A new class of orally available allosteric inhibitors reduces heart muscle hypercontractility, the...
Elmentve itt :
| Szerzők: |
Pálinkás Eszter Dalma Sepp Róbert Olivotto Iacopo |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2023
|
| Sorozat: | CARDIOLOGIA HUNGARICA
53 No. 4 |
| Tárgyszavak: | |
| doi: | 10.26430/CHUNGARICA.2023.53.4.337 |
| mtmt: | 34154906 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/28333 |
Hasonló tételek
-
Genetic diagnosis in hypertrophic cardiomyopathy two steps forward, one step back /
Szerző: Hategan Lídia, et al.
Megjelent: (2021) -
Genetic Testing and Counselling in Hypertrophic Cardiomyopathy Frequently Asked Questions /
Szerző: Girolami Francesca, et al.
Megjelent: (2023) -
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
Szerző: Desai Milind Y, et al.
Megjelent: (2025) -
Clinical scenarios of hypertrophic cardiomyopathy-related mortality Relevance of age and stage of disease at presentation /
Szerző: Zampieri Mattia, et al.
Megjelent: (2023) -
The Influence of Genotype on the Phenotype, Clinical Course, and Risk of Adverse Events in Children with Hypertrophic Cardiomyopathy
Szerző: Girolami Francesca, et al.
Megjelent: (2022)